妊娠期SARS-CoV-2感染管理临床实践指南质量的系统综述与批判性评价
该系统综述检索截至2022年2月15日的Medline、Scopus和ISI Web of Science数据库,纳入28部妊娠期SARS-CoV-2感染管理临床实践指南,使用AGREE II工具评价质量,发现各指南在多个管理方面存在显著异质性,仅9部指南的首次总体评估标准化领域得分>60%。
要点
- 所有纳入指南均推荐仅对重症患者住院治疗。
- 77.1%(7/9)指南推荐对有症状孕妇使用低分子肝素进行血栓预防。
- 各指南一致不推荐仅因母体感染而行剖宫产,并推荐在初次系列疫苗接种后至少6个月接种疫苗加强针。
核心结论
- 已发表的妊娠期SARS-CoV-2感染管理临床实践指南在部分主要管理方面存在显著异质性。
研究设计与样本
- 系统综述,检索Medline、Scopus和ISI Web of Science数据库至2022年2月15日。
- 纳入标准为妊娠期SARS-CoV-2感染管理的临床实践指南,共纳入28部指南。
- 使用AGREE II工具进行偏倚风险和质量评价,以Amer等提出的>60%总体指南评分为推荐(质量良好)的截断值。
主要发现
- 所有指南均推荐仅对重症疾病住院治疗。
- 46.1%(6/13)指南建议SARS-CoV-2感染后进行胎儿生长超声检查,而23.1%(3/13)不支持该做法。
- 77.1%(7/9)指南推荐对有症状孕妇使用低分子肝素进行血栓预防。
- 18.1%(2/11)指南建议从妊娠39周起择期引产,而45.4%(5/11)不推荐择期引产,除非合并其他产科指征。
- 27%(3/11)指南建议缩短第二产程,18.1%(2/11)支持主动用力。
关键数值与推荐
- 所有指南均推荐仅对重症疾病住院治疗。
- 46.1%(6/13)指南建议SARS-CoV-2感染后进行胎儿生长超声检查,23.1%(3/13)指南不支持该做法。
- 77.1%(7/9)指南推荐对有症状孕妇使用低分子肝素进行血栓预防。
- 无指南推荐仅因早孕期SARS-CoV-2感染而给予皮质类固醇,除非存在特定产科指征。
- 18.1%(2/11)指南建议从妊娠39周起择期引产,45.4%(5/11)指南不推荐择期引产,除非合并其他产科指征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically identify and critically assess the quality of clinical practice guidelines for the management of SARS-CoV-2 infection in pregnancy. DATA SOURCES: Medline, Scopus, and ISI Web of Science databases were searched until February 15, 2022. STUDY ELIGIBILITY CRITERIA: Inclusion criteria were clinical practice guidelines on the management of SARS-CoV-2 infection in pregnancy. The risk of bias and quality assessments of the included clinical practice guidelines were performed using the Appraisal of Guidelines for REsearch and Evaluation II tool, which is considered the gold standard for quality assessment of clinical practice guidelines. To define a clinical practice guideline as of good quality, we adopted the cutoff score proposed by Amer et al: if the overall clinical practice guideline score was >60%, it was recommended. METHODS: The following clinical points related to the management of pregnant women with SARS-CoV-2 infection were addressed: criteria for maternal hospitalization, recommendations for follow-up fetal growth scan, specific recommendations against invasive procedures, management of labor, timing of delivery, postpartum care, and vaccination strategy. RESULTS: A total of 28 clinical practice guidelines were included. All recommended hospitalization only for severe disease; 46.1% (6/13) suggested a fetal growth scan after SARS-CoV-2 infection, whereas 23.1% (3/13) did not support this practice. Thromboprophylaxis with low-molecular-weight heparin was recommended in symptomatic women by 77.1% (7/9) of the clinical practice guidelines. None of the guidelines recommended administering corticosteroids only for the presence of SARS-CoV-2 infection in preterm gestation, unless specific obstetrical indication exists. Elective induction of labor from 39 weeks of gestation was suggested by 18.1% (2/11) of the clinical practice guidelines included in the present review, whereas 45.4% (5/11) did not recommend elective induction unless other obstetrical indications coexisted. There were 27% (3/11) of clinical practice guidelines that suggested shortening of the second stage of labor, and active pushing was supported by 18.1% (2/11). There was general agreement among the clinical practice guidelines in not recommending cesarean delivery only for the presence of maternal infection and in recommending vaccine boosters at least 6 months after the primary series of vaccination. The Appraisal of Guidelines for REsearch and Evaluation II standardized domain scores for the first overall assessment of clinical practice guidelines had a mean of 50% (standard deviation±21.82%), and 9 clinical practice guidelines scored >60%. CONCLUSION: A significant heterogeneity was found in some of the main aspects of the management of SARS-CoV-2 infection in pregnancy, as reported by the published clinical practice guidelines.
引用
- Di Girolamo R, Khalil A, Rizzo G, et al. Systematic review and critical evaluation of quality of clinical practice guidelines on the management of SARS-CoV-2 infection in pregnancy. Am J Obstet Gynecol MFM. 2022. PMID: 35504493. doi:10.1016/j.ajogmf.2022.100654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。